Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCPVax plus nivolumab versus standard chemotherapy in second-line advanced non-small cell lung cancer
2019-003805-82Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of UCPVax and nivolumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (2 arms), sponsored by CHU de Besançon. Primary endpoint: Progression-free survival rate at 6 months. Started Jan 2020; status: completed.
02
Drugs
UCPVaxnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on 2019-003805-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003805-82.